Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis
Sponsored by Ablynx, a Sanofi company
About this trial
Last updated 12 years ago
Study ID
3242K1-2000
Status
Completed
Type
Interventional
Phase
Phase 1/Phase 2
Placebo
Yes
Accepting
18 to 80 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 15 years ago
What is this trial about?
The purpose of this study is to evaluate the safety and efficacy of ATN-103 when
administered to subjects with active rheumatoid arthritis compared with placebo. All
subjects must be on a stable dose and route of methotrexate.
What are the participation requirements?
Inclusion Criteria
- Clinical diagnosis of active rheumatoid arthritis on a stable background of methotrexate (7.5-25 mg weekly).
Exclusion Criteria
- Any significant health problem other than rheumatoid arthritis
- Any clinically significant laboratory abnormalities
- Any prior use of B cell-depleting therapy